Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Life Sci ; 351: 122837, 2024 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-38879156

RESUMO

AIM: Chronic sympathetic stimulation has been identified as a primary factor in the pathogenesis of cardiac hypertrophy (CH). However, there is no appropriate treatment available for the management of CH. Recently, it has been revealed that pyruvate kinase M2 (PKM2) plays a significant role in cardiac remodeling, fibrosis, and hypertrophy. However, the therapeutic potential of selective PKM2 inhibitor has not yet been explored in cardiac hypertrophy. Thus, in the current study, we have studied the cardioprotective potential of Compound 3K, a selective PKM2 inhibitor in isoproterenol-induced CH model. METHODS: To induce cardiac hypertrophy, male Wistar rats were subcutaneously administered isoproterenol (ISO, 5 mg/kg/day) for 14 days. Compound 3K at dosages of 2 and 4 mg/kg orally was administered to ISO-treated rats for 14 days to explore its effects on various parameters like ECG, ventricular functions, hypertrophic markers, histology, inflammation, and protein expression were performed. RESULTS: Fourteen days administration of ISO resulted in the induction of CH, which was evidenced by alterations in ECG, ventricular dysfunctions, increase in hypertrophy markers, and fibrosis. The immunoblotting of hypertrophy heart revealed the significant rise in PKM2 and reduction in PKM1 protein expression. Treatment with Compound 3K led to downregulation of PKM2 and upregulation of PKM1 protein expression. Compound 3K showed cardioprotective effects by improving ECG, cardiac functions, hypertrophy markers, inflammation, and fibrosis. Further, it also reduced cardiac expression of PKM2-associated splicing protein, HIF-1α, and caspase-3. CONCLUSION: Our findings suggest that Compound 3K has a potential cardioprotective effect via PKM2 inhibition in isoproterenol-induced CH.


Assuntos
Cardiomegalia , Isoproterenol , Piruvato Quinase , Ratos Wistar , Animais , Isoproterenol/toxicidade , Masculino , Ratos , Cardiomegalia/induzido quimicamente , Cardiomegalia/tratamento farmacológico , Cardiomegalia/prevenção & controle , Cardiomegalia/metabolismo , Piruvato Quinase/metabolismo , Piruvato Quinase/antagonistas & inibidores , Cardiotônicos/farmacologia , Transdução de Sinais/efeitos dos fármacos , Fibrose
2.
AAPS PharmSciTech ; 25(5): 121, 2024 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-38816555

RESUMO

Periodontal disease is a multifactorial pathogenic condition involving microbial infection, inflammation, and various systemic complications. Here, a systematic and comprehensive review discussing key-points such as the pros and cons of conventional methods, new advancements, challenges, patents and products, and future prospects is presented. A systematic review process was adopted here by using the following keywords: periodontal diseases, pathogenesis, models, patents, challenges, recent developments, and 3-D printing scaffolds. Search engines used were "google scholar", "web of science", "scopus", and "pubmed", along with textbooks published over the last few decades. A thorough study of the published data rendered an accurate and deep understanding of periodontal diseases, the gap of research so far, and future opportunities. Formulation scientists and doctors need to be interconnected for a better understanding of the disease to prescribe a quality product. Moreover, prime challenges (such as a lack of a vital testing model, scarcity of clinical and preclinical data, products allowing for high drug access to deeper tissue regions for prolonged residence, lack of an international monitoring body, lack of 4D or time controlled scaffolds, and lack of successful AI based tools) exist that must be addressed for designing new quality products. Generally, several products have been commercialized to treat periodontal diseases with certain limitations. Various strategic approaches have been attempted to target certain delivery regions, maximize residence time, improve efficacy, and reduce toxicity. Conclusively, the current review summarizes valuable information for researchers and healthcare professional to treat a wide range of periodontal diseases.


Assuntos
Patentes como Assunto , Doenças Periodontais , Humanos , Doenças Periodontais/tratamento farmacológico , Bolsa Periodontal/tratamento farmacológico , Animais , Impressão Tridimensional
3.
Toxicol Appl Pharmacol ; 485: 116905, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38521371

RESUMO

Myocardial infarction (MI) or heart attack arises from acute or chronic prolonged ischemic conditions in the myocardium. Although several risk factors are associated with MI pathophysiology, one of the risk factors is an imbalance in the oxygen supply. The current available MI therapies are still inadequate due to the complexity of MI pathophysiology. Pyruvate kinase M2 (PKM2) has been implicated in numerous CVDs pathologies. However, the effect of specific pharmacological intervention targeting PKM2 has not been studied in MI. Therefore, in this study, we explored the effect of compound 3K, a PKM2-specific inhibitor, in isoproterenol-induced acute MI model. In this study, in order to induce MI in rats, isoproterenol (ISO) was administered at a dose of 100 mg/kg over two days at an interval of 24 h. Specific PKM2 inhibitor, compound 3K (2 and 4 mg/kg), was administered in MI rats to investigate its cardioprotective potential. After the last administration of compound 3K, ECG and hemodynamic parameters were recorded using a PV-loop system. Cardiac histology, western blotting, and plasmatic cardiac damage markers were evaluated to elucidate the underlying mechanisms. Treatment of compound 3K significantly reduced ISO-induced alterations in ECG, ventricular functions, cardiac damage, infarct size, and cardiac fibrosis. Compound 3K treatment produced significant increase in PKM1 expression and decrease in PKM2 expression. In addition, HIF-1α, caspase-3, c-Myc, and PTBP1 expression were also reduced after compound 3K treatment. This study demonstrates the cardioprotective potential of compound 3K in MI, and its mechanisms of cardioprotective action.


Assuntos
Cardiotônicos , Isoproterenol , Infarto do Miocárdio , Piruvato Quinase , Animais , Isoproterenol/toxicidade , Infarto do Miocárdio/induzido quimicamente , Infarto do Miocárdio/prevenção & controle , Infarto do Miocárdio/patologia , Masculino , Ratos , Piruvato Quinase/metabolismo , Piruvato Quinase/antagonistas & inibidores , Cardiotônicos/farmacologia , Cardiotônicos/uso terapêutico , Ratos Wistar , Miocárdio/patologia , Miocárdio/metabolismo , Miocárdio/enzimologia , Modelos Animais de Doenças , Ratos Sprague-Dawley , Inibidores de Proteínas Quinases/farmacologia , Hormônios Tireóideos
4.
Naunyn Schmiedebergs Arch Pharmacol ; 397(1): 145-159, 2024 01.
Artigo em Inglês | MEDLINE | ID: mdl-37382601

RESUMO

Myocardial infarction (MI) is a major cause of mortality and disability globally. MI results from acute or chronic myocardial ischemia characterized by an imbalance of oxygen demand and supply, leading to irreversible myocardial injury. Despite several significant efforts in the understanding of MI, the therapy of MI is not satisfactory due to its complicated pathophysiology. Recently, therapeutic potential of targeting pyruvate kinase M2 (PKM2) has been postulated in several cardiovascular diseases. PKM2 gene knockout and expression studies implicated the role of PKM2 in MI. However, the effects of pharmacological interventions targeting PKM2 have not been investigated in MI. Therefore, in the present study, effect of PKM2 inhibitor has been investigated in the MI along with elucidation of possible mechanism(s). MI in rats was induced by administrations of isoproterenol (ISO) at a dose of 100 mg/kg s.c. for two consecutives days at 24-h interval. At the same time, shikonin (PKM2 inhibitor) was administered at 2 and 4 mg/kg in ISO-induced MI rats. After the shikonin treatment, the ventricular functions were measured using a PV-loop system. Plasma MI injury markers, cardiac histology, and immunoblotting were performed to elucidate the molecular mechanism. Treatment of shikonin 2 and 4 mg/kg ameliorated cardiac injury, reduced infarct size, biochemical alterations, ventricular dysfunction, and cardiac fibrosis in ISO-induced MI. Expression of PKM2 in the ventricle was reduced while PKM1 expression increased in the shikonin treated group, indicating PKM2 inhibition restores PKM1 expression. In addition, PKM splicing protein (hnRNPA2B1 & PTBP1), HIF-1α, and caspase-3 expression were reduced after shikonin treatment. Our findings suggest that pharmacological inhibition of PKM2 with shikonin could be a potential therapeutic strategy to treat MI.


Assuntos
Infarto do Miocárdio , Piruvato Quinase , Ratos , Animais , Piruvato Quinase/genética , Piruvato Quinase/metabolismo , Isoproterenol/toxicidade , Infarto do Miocárdio/induzido quimicamente , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/metabolismo , Hipóxia , Apoptose , Fibrose , Inflamação
5.
Curr Med Chem ; 2023 Jul 27.
Artigo em Inglês | MEDLINE | ID: mdl-37497712

RESUMO

Alzheimer's disease (AD) is a complex neurological disorder that results in cognitive decline. The incidence rates of AD have been increasing, particularly among individuals 60 years of age or older. In June 2021, the US FDA approved aducanumab, the first humanized monoclonal antibody, as a potential therapeutic option for AD. Clinical trials have shown this drug to effectively target the accumulation of Aß (beta-amyloid) plaques in the brain, and its effectiveness is dependent on the dosage and duration of treatment. Additionally, aducanumab has been associated with improvements in cognitive function. Biogen, the pharmaceutical company responsible for developing and marketing aducanumab, has positioned it as a potential breakthrough for treating cerebral damage in AD. However, the drug has raised concerns due to its high cost, limitations, and potential side effects. AD is a progressive neurological condition that affects memory, cognitive function, and behaviour. It significantly impacts the quality of life of patients and caregivers and strains healthcare systems. Ongoing research focuses on developing disease-modifying therapies that can halt or slow down AD progression. The pathogenesis of AD involves various molecular cascades and signaling pathways. However, the formation of extracellular amyloid plaques is considered a critical mechanism driving the development and progression of the disease. Aducanumab, as a monoclonal antibody, has shown promising results in inhibiting amyloid plaque formation, which is the primary pathological feature of AD. This review explores the signaling pathways and molecular mechanisms through which aducanumab effectively prevents disease pathogenesis in AD.

6.
Mar Drugs ; 21(3)2023 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-36976242

RESUMO

Cardiovascular diseases (CVDs) are among the most impactful illnesses globally. Currently, the available therapeutic option has several side effects, including hypotension, bradycardia, arrhythmia, and alteration in different ion concentrations. Recently, bioactive compounds from natural sources, including plants, microorganisms, and marine creatures, have gained a lot of interest. Marine sources serve as reservoirs for new bioactive metabolites with various pharmacological activities. The marine-derived compound such as omega-3 acid ethyl esters, xyloketal B, asperlin, and saringosterol showed promising results in several CVDs. The present review focuses on marine-derived compounds' cardioprotective potential for hypertension, ischemic heart disease, myocardial infarction, and atherosclerosis. In addition to therapeutic alternatives, the current use of marine-derived components, the future trajectory, and restrictions are also reviewed.


Assuntos
Doenças Cardiovasculares , Hipertensão , Humanos , Doenças Cardiovasculares/tratamento farmacológico
7.
Environ Sci Pollut Res Int ; 30(55): 116421-116439, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35091945

RESUMO

The rate of transformation of natural land use land cover (LULC) to the built-up areas is very high in the peri-urban areas of Indian metropolitan cities. Delhi National Capital Region (Delhi NCR) is an inter-state planning region, located in the central part of India. The region has attracted a larger chunk of population by providing better economic opportunities during last few decades. This has resulted in large-scale transformation of the LULC pattern in the region. Thus, this study is intended to analyze and quantify the LULC change and its drivers in the peri-urban areas of Delhi NCR using Landsat datasets. Based on an extensive literature survey, several potential drivers of the LULC change have been analyzed using ordinary least squares (OLS) and geographical weighted regression (GWR) for the Delhi NCR. The results from LULC classification showed that the built-up area has increased from 1.67 to 7.12% of the total area of Delhi NCR during 1990-2018 while other LULC types have declined significantly. The OLS results showed that migration and employment in the tertiary sector are the most important drivers of built-up expansion in the study area. The standard residuals and local R2 results from GWR showed spatial heterogeneity among the coefficients of the explanatory variables throughout the study area. This study can be helpful for the urban policy makers and planners for making better master plan of Delhi NCR and other cities of developing countries.


Assuntos
Monitoramento Ambiental , Regressão Espacial , Monitoramento Ambiental/métodos , Cidades , Índia , Emprego , Urbanização , Conservação dos Recursos Naturais
8.
Environ Sci Pollut Res Int ; 30(55): 116617-116643, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35854070

RESUMO

Ecosystem services provided by wetlands are essential for communities living near wetlands, especially in an underdeveloped semi-arid landscape. The land use land cover changes and ecosystem degradation and water quality change over the past few decades have had immense effects on declining wetland ecosystem services. With the degradation, it is exerting superfluous effects on wetland communities including loss of livelihood, and decline in other wetland services like fishing, aquaculture, fuelwood, fodder, and many more. The present study attempts to assess the changing nature of wetland health, water quality, and declining ecosystem services of Mount Abu wetlands in Rajasthan, India. For assessing the change of wetland extent, we have used the remote sensing-based data for preparation of land use land cover change from 1992 to 2020. The water samples have been collected from the wetland, and different biophysical parameters of the water have been tested in the laboratory. A questionnaire-based household survey has been conducted to understand the perception of the wetland communities on the loss of ecosystem services over three decades. Further, a correlation and cluster assessment has been conducted to understand the degradation of wetland health in the selected wetlands. The study results indicated deteriorating conditions of wetland health and declining ecosystem services in the study area over the time periods. The land use land cover change analysis indicated a decrease in the spatial extent of the wetlands in the study area. Wetland communities are being affected due to the degradation of wetland health. The study recommended executing a wetland management plan for long-term conservation and livelihood management for the Mount Abu wetlands and communities.


Assuntos
Ecossistema , Áreas Alagadas , Qualidade da Água , Conservação dos Recursos Naturais/métodos , Monitoramento Ambiental/métodos , Índia
9.
J Cardiovasc Transl Res ; 16(2): 382-402, 2023 04.
Artigo em Inglês | MEDLINE | ID: mdl-36178660

RESUMO

Cardiovascular diseases (CVDs) are the world's leading cause of death, accounting for 32% of all fatalities. Although therapeutic agents are available for CVDs, however, most of them have significant limitations such as the time-dependency effect, hypotension, and bradycardia. To overcome the limitations of current pharmacological therapies, new molecular targets and pathways need to be identified and investigated to provide better treatment options for CVDs. Recent evidence suggested the involvement of pyruvate kinase M2 (PKM2) and targeting PKM2 by its modulators (inhibitors and activators) has shown promising results in several CVDs. PKM2 regulates gene activation in the context of apoptosis, mitosis, hypoxia, inflammation, and metabolic reprogramming. PKM2 modulators might have a significant impact on the molecular pathways involved in CVD pathogenesis. Therefore, PKM2 modulators can be one of the therapeutic options for CVDs. This review provides an insight into PKM2 involvement in various CVDs along with their therapeutic potential.


Assuntos
Doenças Cardiovasculares , Piruvato Quinase , Humanos , Piruvato Quinase/genética , Piruvato Quinase/metabolismo , Inflamação , Apoptose
10.
Respir Med ; 204: 107007, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36265420

RESUMO

Asthma prevailed as a common inflammatory disease affecting mainly the lower respiratory tract, with notable inflammation in the upper airways leading to significant morbidity and mortality. An extensive search for a new therapeutic target is continuously being carried out. Still, the majority have failed in the trials, and eventually, the drugs, including ß2-adrenergic agonists, muscarinic antagonists, and certain corticosteroids, remain the backbone for asthma control. Numerous endogenous factors aid in maintaining the normal homeostasis of the lungs and prevents disease progression. One among them is the apolipoproteins which are different sets of lipoprotein moieties that not only aid in the transport and metabolism of lipids but also impart immunomodulatory roles in various pathologies. Modern research joins the links between the immunomodulatory nature of apolipoproteins in chronic respiratory diseases like asthma and COPD, which can assist in ameliorating the disease progression. Recent studies have elucidated the protective roles of apoA-I and apoE in asthma. This has enabled the utilization of certain apolipoprotein-mimetic peptides to treat these severe pulmonary diseases in the long run. In this review, we have described the prominent and probable mechanistic roles of apolipoproteins like apoA-I, apoB, apoE, apoJ, and apoM in the pathogenesis and treatment of asthma along with the development of apoA-I and apoE-mimetics as a cardinal treatment strategy for eosinophilic as well as corticosteroid resistant neutrophilic asthma.


Assuntos
Apolipoproteína A-I , Asma , Humanos , Apolipoproteína A-I/metabolismo , Apolipoproteína A-I/uso terapêutico , Apolipoproteínas E/metabolismo , Apolipoproteínas E/uso terapêutico , Apolipoproteínas/uso terapêutico , Asma/tratamento farmacológico , Peptídeos , Progressão da Doença
11.
Chem Biol Interact ; 368: 110231, 2022 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-36288778

RESUMO

The human microbiota is fundamental to correct immune system development and balance. Dysbiosis, or microbial content alteration in the gut and respiratory tract, is associated with immune system dysfunction and lung disease development. The microbiota's influence on human health and disease is exerted through the abundance of metabolites produced by resident microorganisms, where short-chain fatty acids (SCFAs) represent the fundamental class. SCFAs are mainly produced by the gut microbiota through anaerobic fermentation of dietary fibers, and are known to influence the homeostasis, susceptibility to and outcome of many lung diseases. This article explores the microbial species found in healthy human gastrointestinal and respiratory tracts. We investigate factors contributing to dysbiosis in lung illness, and the gut-lung axis and its association with lung diseases, with a particular focus on the functions and mechanistic roles of SCFAs in these processes. The key focus of this review is a discussion of the main metabolites of the intestinal microbiota that contribute to host-pathogen interactions: SCFAs, which are formed by anaerobic fermentation. These metabolites include propionate, acetate, and butyrate, and are crucial for the preservation of immune homeostasis. Evidence suggests that SCFAs prevent infections by directly affecting host immune signaling. This review covers the various and intricate ways through which SCFAs affect the immune system's response to infections, with a focus on pulmonary diseases including chronic obstructive pulmonary diseases, asthma, lung cystic fibrosis, and tuberculosis. The findings reviewed suggest that the immunological state of the lung may be indirectly influenced by elements produced by the gut microbiota. SCFAs represent valuable potential therapeutic candidates in this context.


Assuntos
Asma , Microbioma Gastrointestinal , Humanos , Disbiose/metabolismo , Ácidos Graxos Voláteis/metabolismo , Ácidos Graxos Voláteis/uso terapêutico , Pulmão/metabolismo , Asma/tratamento farmacológico
12.
Bioorg Med Chem Lett ; 59: 128539, 2022 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-35007726

RESUMO

PKM2is considered a desirable target as its enzymatic activation is expected to cause a diminution in tumorigenesis and prevent limitless replication in cancerous cells. However, considering the functional consequences of kinase inhibitors, the design of PKM2 activators has been an attractive strategy that has yielded potent anticancer molecules like DASA-58. Therefore, a new class of boronic acid derivate was developed to elucidate the possible mechanistic link between PKM2 activation and TPI1 activity, which has a significant role in the redox balance in cancer. The present in vitro study revealed that treatment with boronic acid-based compound 1 and DASA-58 was found to activate PKM2 with an AC50 of 25 nM and 52 nM, respectively. Furthermore, at the AC50 concentration of compound 1, we found a significant increase in TPI1 activity and a decrease in GSH and NADP+/NADPH ratio. We also found increased ROS levels and decreased lactate secretion with treatment. Together with these findings, we can presume that compound 1 affects the redox balance by activating PKM2 and TPI1 activity. Implementation of this treatment strategy may improve the effect of chemotherapy in the conditions of ROS induced cancer drug resistance. This study for the first time supports the link between PKM2 and the TPI1 redox balance pathway in oral cancer. Collectively, the study findings provide a novel molecule for PKM2 activation for the therapeutic intervention in oral cancer.


Assuntos
Ácidos Borônicos/farmacologia , Proteínas de Transporte/metabolismo , Proteínas de Membrana/metabolismo , Hormônios Tireóideos/metabolismo , Ácidos Borônicos/química , Relação Dose-Resposta a Droga , Humanos , Estrutura Molecular , Oxirredução , Espécies Reativas de Oxigênio/metabolismo , Relação Estrutura-Atividade , Triose-Fosfato Isomerase/metabolismo , Proteínas de Ligação a Hormônio da Tireoide
13.
Cancer Microenviron ; 12(2-3): 149-167, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31183810

RESUMO

Metabolic reprogramming is a newly emerged hallmark of cancer attaining a recent consideration as an essential factor for the progression and endurance of cancer cells. A prime event of this altered metabolism is increased glucose uptake and discharge of lactate into the cells surrounding constructing a favorable tumor niche. Several oncogenic factors help in promoting this consequence including, pyruvate kinase M2 (PKM2) a rate-limiting enzyme of glycolysis in tumor metabolism via exhibiting its low pyruvate kinase activity and nuclear moon-lightening functions to increase the synthesis of lactate and macromolecules for tumor proliferation. Not only its role in cancer cells but also its role in the tumor microenvironment cells has to be understood for developing the small molecules against it which is lacking with the literature till date. Therefore, in this present review, the role of PKM2 with respect to various tumor niche cells will be clarified. Further, it highlights the updated list of therapeutics targeting PKM2 pre-clinically and clinically with their added limitations. This upgraded understanding of PKM2 may provide a pace for the reader in developing chemotherapeutic strategies for better clinical survival with limited resistance.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...